Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Sequist, Lecia
Item TypeName
Academic Article Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Academic Article Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Academic Article Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
Academic Article Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Academic Article Detection of mutations in EGFR in circulating lung-cancer cells.
Academic Article Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Academic Article Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.
Academic Article Toward noninvasive genomic screening of lung cancer patients.
Academic Article Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Academic Article BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Academic Article Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Academic Article Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Academic Article Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Academic Article EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.
Academic Article Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Academic Article Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Academic Article Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Academic Article Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Academic Article EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
Academic Article First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Academic Article Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.
Concept Protein Kinase Inhibitors
Academic Article Characteristics of lung cancers harboring NRAS mutations.
Academic Article Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
Academic Article Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Academic Article Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Academic Article Acquired resistance to TKIs in solid tumours: learning from lung cancer.
Academic Article Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Academic Article RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Academic Article Rociletinib in EGFR-mutated non-small-cell lung cancer.
Academic Article Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
Academic Article Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
Academic Article Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.
Academic Article The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
Academic Article The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Academic Article Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.
Academic Article Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy.
Academic Article Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
Academic Article Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Academic Article Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Academic Article Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Academic Article Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
Academic Article Update to Rociletinib Data with the RECIST Confirmed Response Rate.
Academic Article Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Academic Article Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.
Academic Article Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Academic Article Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.
Academic Article Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
Academic Article EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Academic Article Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review.
Academic Article Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Academic Article Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Academic Article Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Academic Article Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.
Academic Article Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
Academic Article Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers.
Academic Article The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.
Academic Article Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Academic Article Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.
Academic Article Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.
Academic Article EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Academic Article Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.
Academic Article Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.
Academic Article Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
Academic Article Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.
Academic Article SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Academic Article Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
Academic Article Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Academic Article Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Search Criteria
  • Protein Kinase Inhibitors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.